The impact of olaparib on cellular PARP activity under both aerobic and hypoxic conditions and its ability to enhance the sensitivity of radiation therapy in prostate cancer cells were examined by Gani et al. In vitro, PARP activity was inhibited by olaparib under both hypoxic and aerobic conditions. Here, PARP1 is linked to prostate carcinoma.